Fundraising Fox

Newleos Therapeutics

Boston, US · Founded 2024 · Delaware corporation · 6 known investors

newleostherapeutics.com ↗
Biotech

Founders & leadership

DD
David DonabedianExecutivePartner, NewCo Formation at Longwood Fund
RHRobert Hadfield
Robert HadfieldExecutiveGeneral Counsel & Operating Partner at Longwood Fund
JMJohn McCabe
John McCabeExecutivePortfolio Company CFO & COO at Longwood Fund

Board

CWChristoph Westphal
Christoph WestphalBoard directorCo-Founder & General Partner at Longwood Fund
MC
Ming CheahBoard director
RC
Raymond CamahortBoard director

Investors · 6

DCVC (Data Collective)Palo Alto · $5M – $25M
DCVC BioPalo Alto
Longwood Fundreported · 3 sourcesBostonvia Christoph Westphal · board
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M

Also in the syndicate · 2

Arkin Bio CapitalGoldman Sachs Alternativeslead

Reported raises · per SEC filings

Form D private placements

$93.4M disclosed across 1 round · 2025

▶$93.4MraisedFeb 2025 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David DonabedianExecutive Officer, Director
  • Robert HadfieldExecutive Officer
  • Christoph WestphalDirector
  • Ming CheahDirector
  • Raymond CamahortDirector
  • John McCabeExecutive Officer
Offering amount
$93.4M
Amount sold
$93.4M
First sale
Feb 2025
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Newleos secures $93.5m for neuropsychiatric disorder treatmentspharmaceutical-technology.com · Feb 2025Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche - BioSpacebiospace.com · Feb 2025Newleos Therapeutics Announces $93.5M Series A for Next Generation Mental Health Therapies | Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLPgunder.com · Feb 2025Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicinesbusinesswire.com · Feb 2025

Frequently asked questions

Who are Newleos Therapeutics's investors?
Newleos Therapeutics's investors include DCVC (Data Collective), DCVC Bio, Longwood Fund, Novo Holdings.
How much funding has Newleos Therapeutics raised?
Newleos Therapeutics has disclosed $93.4M raised across 1 round.
Where is Newleos Therapeutics headquartered?
Newleos Therapeutics is headquartered in Boston, US.